Strategic Acquisition ALung was acquired by LivaNova in May 2022 for $10 million with potential milestone-based future payments, indicating a larger corporate distribution and sales reach that can be leveraged for channel partnerships and international markets.

Clinical Need Hemolung RAS provides a less invasive option for CO2 removal and oxygen delivery, supporting ultra-protective ventilation and COPD management, presenting opportunities to engage hospitals seeking alternatives to mechanical ventilation and to expand adoption in ICUs and respiratory care centers.

Financial Momentum Current revenue range and substantial total funding indicate capacity for scale and investment in sales, onboarding, and clinical education programs to accelerate adoption in target US and international markets.

Adjacency Fit Technology aligns with institutions using advanced extracorporeal support, enabling partnerships with large medtech distributors and academic medical centers focused on respiratory failure solutions and critical care innovation.

Market Readiness Past financing rounds and a high-profile acquisition signal investor confidence; combine this with a clear clinical value proposition to craft co-marketing to hospitals, identify payor coverage strategies, and pursue grant-supported deployment pilots.